Venus Medtech (Hangzhou), Inc. Class H
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VMTHF research report →
About the company
Venus Medtech (Hangzhou) Inc. , together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis.
- CEO
- Hou-Sen Lim
- IPO
- 2021
- Employees
- 563
- HQ
- Wanchai, WA, CN
Price Chart
- Market Cap
- $186.06M
- P/E
- -1.61
- P/S
- 2.15
- P/B
- 0.37
- EV/EBITDA
- -3.01
- Div Yield
- 0.00%
- Gross Margin
- 69.05%
- Op Margin
- -112.56%
- Net Margin
- -132.89%
- ROE
- -21.29%
- ROIC
- -14.88%
- Revenue
- $298.87M · -36.52%
- Net Income
- $-397,172,134 · 44.40%
- EPS
- $-0.91 · 44.17%
- Op Income
- $-337,177,361
- FCF YoY
- -1764.03%
- 52W High
- $0.52
- 52W Low
- $0.25
- 50D MA
- $0.42
- 200D MA
- $0.37
- Beta
- 1.15
- Avg Volume
- 878.804
Get TickerSpark's AI analysis on VMTHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VMTHF coverage
Recent articles, reports, and earnings notes.
No research on VMTHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VMTHF report →Similar companies
Peers in the same neighborhood.